Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
halobetasol propionate lotion 0.05%
- Development stage
- Approved
- Lead developer
- Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Halobetasol propionate lotion 0.05% is a super-potent (Class I) topical corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Developed by Therapeutics, Inc. in collaboration with Ferndale Laboratories, and marketed under the brand name Ultravate, the drug contains halobetasol propionate, a synthetic corticosteroid that binds to glucocorticoid receptors to exert anti-inflammatory, antipruritic, and vasoconstrictive effects. It is formulated as a topical lotion applied twice daily for up to two weeks. Clinical studies have demonstrated its efficacy in reducing the severity of plaque psoriasis, though it is associated with a risk of hypothalamic-pituitary-adrenal (HPA) axis suppression.
- Brand names
- HalobexHalovateUltravate
- Other names
- halobetasol propionate lotion 0.05%halobetasol proprionate lotion 0.05%ulobetasol propionate lotion 0.05%
02
Targets
FOS (Activator Protein 1)ANXA1 (Annexin A1)GR (Glucocorticoid receptor)NF-κBPLA2 (Phospholipase A2 group IID)
Beyond the preview
Go deeper on halobetasol propionate lotion 0.05%.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on halobetasol propionate lotion 0.05%.